ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

16 Tips from 16 Years Sick

Fibromyalgia Fare Fit for All Seasons

New Study Shows Artificial Sweeteners Lead to Diabetes

Essential Oils — An Effective and Healthy Option to Treat Headaches

Antioxidant treatment could halt neurodegeneration in early Parkinson's

Higher vitamin D levels associated with less severe disease in NAFLD patients

Krill Oil: Make This Omega-3 Supplement Part of Your Health Regimen

How zinc helps fight esophageal cancer

Everything You Need to Know About Black Cohosh

Low vitamin D levels predict ED in diabetics

 
Print Page
Email Article

Large Scale Trials of Alzheimer's “Vaccine” at Hundreds of Centers in US, Canada, 20 Other Countries

  [ 1 vote ]   [ Discuss This Article ]
www.ProHealth.com • January 8, 2009


Therapy involves periodic infusion of plaque-targeting antibodies

Researchers at hundreds of locations across the US & Canada and in 20 other countries are conducting/recruiting for a constellation of Phase III (large scale) trials of the drug bapineuzumab.

The drug is defined as “a humanized monoclonal antibody,” which is designed to bind to and clear beta amyloid peptide (Alzheimer’s brain plaques), and “to provide antibodies to beta amyloid directly to the patient.” The goal – to determine the drug’s ability to intervene in the progression of Alzheimer’s disease in patients who are and are not Apolipoprotein E4 carriers.

Bapineuzumab is delivered in a series of infusions. This approach is called “passive immunization,” since the body is receiving the antibodies via the drug, rather then generating the antibodies itself, according to Dr. Douglas Scharre, MD, a neurologist at Ohio State University Medical Center who is leading OSU’s involvement in the research. To view a brief video on the trial released recently by OSU, click here.

“The early results from animal studies have been very promising, and we are now looking to see if we achieve the same outcomes with our patients,” says Dr. Scharre. “The first goal is to find a way to prevent the progression of the disease. If we can’t prevent it, studies have shown that delaying the onset for five years would result in a 50 percent reduction in the number of cases.”

The Phase III trials include:

• “Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease” (Clinicaltrials.gov ID NCT00575055) involving centers across the US and Canada - is a “double-blind, placebo controlled, randomized, outpatient, multiple dose study in male and female patients ages 50 to less than 89 years with mild to moderate AD who are Apolipoprotein E4 carriers… Patients will be randomized to receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.”

• “Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease” (Clinicaltrials.gov ID NCT00574132) – also involving US and Canadian centers, is for patients who are not Apolipoprotein E4 carriers.

• “Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients” (Clinicaltrials.gov ID NCT00676143) – involving centers in 20 countries outside the US, for patients who are Apolipoprotein E4 carriers

• “Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients” (Clinicaltrials.gov ID NCT00667810) – involving centers in 20 countries outside the US, for patients who are not Apolipoprotein E4 carriers.

For more information and to review the listings of trial centers, visit the ClinicalTrials.gov listings for these studies. The studies are sponsored by Elan Pharmaceuticals in the US/Canada and Wyeth elsewhere.

Sources: Jan 5, 2009 news release, Ohio State University College of Medicine; ClinicalTrials.gov; Alzheimer Research Forum.




Post a Comment

Featured Products From the ProHealth Store
Vitamin D3 Extreme™ Optimized Curcumin Longvida® Mitochondria Ignite™ with NT Factor®


Article Comments



Be the first to comment on this article!

Post a Comment


 
Optimized Curcumin Longvida with Omega-3

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Vitamin D3 Extreme™ Vitamin D3 Extreme™
50,000 IU Vitamin D3 - Prescription Strength

Natural Remedies

Enhance Eyelashes Naturally Enhance Eyelashes Naturally
Could a B-12 Deficiency Be Causing Your Symptoms? Could a B-12 Deficiency Be Causing Your Symptoms?
Guarding Against the Dangers of Vitamin D Deficiency Guarding Against the Dangers of Vitamin D Deficiency
Improve Cardiovascular and Metabolic Health with Omega-7 Improve Cardiovascular and Metabolic Health with Omega-7
Natural Relief for Soreness, Pain and Swelling - Putting Out the Fire Natural Relief for Soreness, Pain and Swelling - Putting Out the Fire

CONTACT US
ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
SHOP WITH CONFIDENCE
Credit Card Processing
SUBSCRIBE TO OUR NEWSLETTERS
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map